Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor.
Iwai K, Nambu T, Dairiki R, Ohori M, Yu J, Burke K, Gotou M, Yamamoto Y, Ebara S, Shibata S, Hibino R, Nishizawa S, Miyazaki T, Homma M, Oguro Y, Imada T, Cho N, Uchiyama N, Kogame A, Takeuchi T, Kurasawa O, Yamanaka K, Niu H, Ohashi A. Iwai K, et al. Among authors: ohashi a. Sci Adv. 2019 May 22;5(5):eaav3660. doi: 10.1126/sciadv.aav3660. eCollection 2019 May. Sci Adv. 2019. PMID: 31131319 Free PMC article.
Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens.
Kashima Y, Togashi Y, Fukuoka S, Kamada T, Irie T, Suzuki A, Nakamura Y, Shitara K, Minamide T, Yoshida T, Taoka N, Kawase T, Wada T, Inaki K, Chihara M, Ebisuno Y, Tsukamoto S, Fujii R, Ohashi A, Suzuki Y, Tsuchihara K, Nishikawa H, Doi T. Kashima Y, et al. Among authors: ohashi a. Sci Rep. 2021 Jan 11;11(1):341. doi: 10.1038/s41598-020-79385-w. Sci Rep. 2021. PMID: 33431933 Free PMC article.
Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer.
Kashima Y, Shibahara D, Suzuki A, Muto K, Kobayashi IS, Plotnick D, Udagawa H, Izumi H, Shibata Y, Tanaka K, Fujii M, Ohashi A, Seki M, Goto K, Tsuchihara K, Suzuki Y, Kobayashi SS. Kashima Y, et al. Among authors: ohashi a. Cancer Res. 2021 Sep 15;81(18):4835-4848. doi: 10.1158/0008-5472.CAN-20-2811. Epub 2021 Jul 9. Cancer Res. 2021. PMID: 34247147 Free PMC article.
Impacts of the STING-IFNAR1-STAT1-IRF1 pathway on the cellular immune reaction induced by fractionated irradiation.
Du J, Kageyama SI, Yamashita R, Hirata H, Hakozaki Y, Okumura M, Motegi A, Hojo H, Nakamura M, Hirano Y, Sunakawa H, Minamide T, Kotani D, Tanaka K, Yano T, Kojima T, Ohashi A, Tsuchihara K, Akimoto T. Du J, et al. Among authors: ohashi a. Cancer Sci. 2022 Apr;113(4):1352-1361. doi: 10.1111/cas.15297. Epub 2022 Feb 20. Cancer Sci. 2022. PMID: 35133062 Free PMC article.
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.
Udagawa H, Hasako S, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi SS. Udagawa H, et al. Among authors: ohashi a. Mol Cancer Res. 2019 Nov;17(11):2233-2243. doi: 10.1158/1541-7786.MCR-19-0419. Epub 2019 Aug 29. Mol Cancer Res. 2019. PMID: 31467113 Free PMC article.
A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery.
Iwai K, Nambu T, Kashima Y, Yu J, Eng K, Miyamoto K, Kakoi K, Gotou M, Takeuchi T, Kogame A, Sappal J, Murai S, Haeno H, Kageyama SI, Kurasawa O, Niu H, Kannan K, Ohashi A. Iwai K, et al. Among authors: ohashi a. Sci Adv. 2021 May 21;7(21):eabf0197. doi: 10.1126/sciadv.abf0197. Print 2021 May. Sci Adv. 2021. PMID: 34020950 Free PMC article.
544 results